Y Abdou, A Goudarzi, JX Yu, S Upadhaya… - NPJ Breast …, 2022 - search.proquest.com
The development of immunotherapy agents has revolutionized the field of oncology. The only FDA-approved immunotherapeutic approach in breast cancer consists of immune …
Y Abdou, A Goudarzi, JX Yu, S Upadhaya… - NPJ Breast …, 2022 - ncbi.nlm.nih.gov
The development of immunotherapy agents has revolutionized the field of oncology. The only FDA-approved immunotherapeutic approach in breast cancer consists of immune …
Y Abdou, A Goudarzi, JX Yu, S Upadhaya… - NPJ Breast …, 2022 - search.ebscohost.com
The development of immunotherapy agents has revolutionized the field of oncology. The only FDA-approved immunotherapeutic approach in breast cancer consists of immune …
Y Abdou, A Goudarzi, JX Yu, S Upadhaya… - NPJ Breast …, 2022 - europepmc.org
The development of immunotherapy agents has revolutionized the field of oncology. The only FDA-approved immunotherapeutic approach in breast cancer consists of immune …
Y Abdou, A Goudarzi, JX Yu, S Upadhaya… - NPJ breast …, 2022 - pubmed.ncbi.nlm.nih.gov
The development of immunotherapy agents has revolutionized the field of oncology. The only FDA-approved immunotherapeutic approach in breast cancer consists of immune …
Y Abdou, A Goudarzi, JX Yu, S Upadhaya… - NPJ Breast …, 2022 - europepmc.org
The development of immunotherapy agents has revolutionized the field of oncology. The only FDA-approved immunotherapeutic approach in breast cancer consists of immune …